Back to News
Market Impact: 0.35
AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AstraZeneca and HUTCHMED reported Phase 3 results showing that Tagrisso (osimertinib) plus Orpathys (savolitinib) significantly improved progression-free and overall survival in patients with EGFR-mutated non-small cell lung cancer. The excerpt provides no effect sizes or further details on the patient population.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
AZN0.70
HCM0.70
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs